Title:Network Pharmacology, Molecular Docking and in vivo-based Analysis on the Effects of the MBZM-N-IBT for Arthritis
Volume: 21
Issue: 2
Author(s): Alok Kumar Moharana, Mahendra Gaur, Tapas Kumar Mohapatra, Rudra Narayan Dash and Bharat Bhusan Subudhi*
Affiliation:
- Drug Development and Analysis Lab, School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be
University), Bhubaneswar, 751029, India
Keywords:
Arthritis, inflammation, MBZM-N-IBT, network pharmacology, molecular docking, in vivo.
Abstract:
Introduction: Arthritis is the cause of morbidity associated with Chikungunya virus
(CHIKV) infection. It persists even after the virus has been cleared from the body. MBZM-NIBT
was earlier shown to inhibit (CHIKV) infection in vitro and in vivo.
Objective: The objective of this study is to determine the ability of MBZM-N-IBT to manage
arthritis independent of CHIKV infection.
Method: The acute toxicity of MBZM-N-IBT was determined to find a permissible oral dose.
Effects against inflammation and arthritis were determined in relevant preclinical models. Network
pharmacology was used to propose possible modes of action.
Result: It showed no acute toxicity orally, with an estimated LD50 of more than 5000 mg/kg in
rats. It significantly reduced inflammation. Its effect against Complete Freund's Adjuvant (CFA)
induced arthritis was comparable to that of Diclofenac sodium. Network pharmacology analysis
revealed that MBZM-N-IBT can potentially interfere with multiple targets and pathways.
MMP12 and CTSD were found to be the most probable hub targets of MBZM-N-IBT for its
effect against arthritis.
Conclusion: In conclusion, MBZM-N-IBT is safe at 50 mg/kg and can manage arthritis independent
of CHIKV infection through modulation of multiple pathways and arthritis-associated
targets.
